cyrilzakka/clinical-trials huggingface dataset:
Effects of Plyometric and High Intensity Interval Training on Sprint Speed, Agility and Power Among Female Fast Bowlers

This study will investigate the comparative effects of plyometric training (PT) and high-intensity interval training (HIIT) on key performance metrics: sprint speed, agility, and power. The research will be conducted as a randomized clinical trial over six months, involving 34 participants recruited from cricket academies.

Participants will be randomly assigned to either the PT or HIIT group. The PT group will perform exercises leveraging the stretch-shortening cycle to enhance explosive power, while the HIIT group will alternate high-intensity activity with recovery periods to improve anaerobic capacity. Standardized tools, including the 40-Yard Sprint Test, Standing Broad Jump, and Agility T-Test, will be used to assess outcomes pre- and post-intervention. Data will be analyzed using SPSS, employing paired t-tests and Mann-Whitney U tests for within- and between-group comparisons

Eligibility Criteria:
Inclusion Criteria:

* Female fast bowlers age 18-25 years
* Active cricketers with at least 2 years of experience in fast bowling (20)
* Active health status, no history of severe injuries

Exclusion Criteria:

* Any history of chronic injuries, musculoskeletal disorders, or conditions that could be exacerbated by high-intensity exercise.
* Participants not regularly training or competing in cricket.
* Females underwent C-section and or having two children will exclude
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years old;
* Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP/TAZO；
* Patients and their families are fully aware of the research content and sign the informed consent form.

Exclusion Criteria:

* Intolerance or serious adverse reactions to antibiotic use;
* Patients who stopped using PIP/TAZO more than 24 hours before delivery;
* Receiving other systemic trial drugs;
* There are other factors that the researchers think are not suitable for inclusion
Immunodeficiency in MS

The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS.

The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS. By understanding this relationship future studies can be designed to create a model of immunosenescence in multiple sclerosis, which could help healthcare providers to predict and assess health risks. Preventative strategies can then be tested to look for ways to prevent these immune-related risks.

Eligibility Criteria:
Inclusion Criteria

* One or more immunoglobulin level results and medical history available
* 18 years of age or older at the time of data collection
* Patients with first symptom MS or other isolated demyelinating syndromes, neuromyelitis optica, or rheumatic-associated CNS inflammation

Exclusion Criteria:

* No evidence of CNS autoimmune disease
* Less than 18 years of age at the time of data abstraction
* Undergoing plasma exchange at the time of any lab tests drawn
Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Evaluate the behavioral effects of ADDERALL XR versus STRATTERA under controlled conditions utilizing the SKAMP deportment scale.


Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of ADHD combined subtype or predominantly hyperactive-impulsive subtype, based on psychiatric evaluation
* Capable of understanding and following classroom instructions
* Generally functioning academically at age-appropriate levels

Exclusion Criteria:

* ADHD, predominantly inattentive subtype
* Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD, severe depressive or severe anxiety disorder
* Documented history of aggressive behavior serious enough to preclude participation in regular classroom activities
* Documented allergies or intolerance to either of the active treatments or tricyclic antidepressants
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.

This is a prospective, non-randomized, pilot study. The target population is adults ≥18 years of age with metastatic non-small cell lung cancer that at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of planned doses of immune checkpoint inhibitor treatment in the first line setting. The study will be conducted at various Atrium Health Wake Forest Baptist Comprehensive Cancer Center locations. Subjects will have blood for ctDNA and immune markers collected at baseline, and every 3 months for up to approximately 6 months. Blood will be collected at disease progression if it occurs prior to 6 months, ensuring that the collection occurs prior to start of subsequent anti-cancer therapy. We will also collect data from standard of care CT scans every 3 months for up to 6 months or until disease progression. In patients undergoing standard of care biopsies, a portion of tumor tissue will be obtained and tested for tumor mutations. Archived tumor tissue collected pre-immunotherapy (if available) will also be tested.

Eligibility Criteria:
Inclusion Criteria

1. Informed consent and HIPAA authorization for release of personal health information signed by the subject. Note: Data from tumor samples, blood samples and radiographic scans prior to enrollment date may be used.
2. Age greater than or equal to18 years at the time of consent.
3. Patients with metastatic non-small cell lung carcinoma have completed first line who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or pembrolizumab combination chemotherapy in the first line setting.
4. Patients are allowed to continue maintenance chemotherapy.
5. Ability to understand and comply with study procedures for the entire length of the study.
6. Known PD-L1 prior to initiation of first-line treatment for NSCLC.

Exclusion Criteria

1. Enrollment/collection of baseline sample earlier than 7 days prior to scheduled last dose of immune checkpoint inhibitor treatment or more than 30 days after last dose of immune checkpoint inhibitor treatment.
2. Patients whose tumors harbor known first line treatment druggable gene abnormalities (e.g. EGFR, BRAF, ALK, ROS1).
3. Patients who have ever received or are currently receiving other types of immunotherapies (nivolumab, ipilimumab, durvalumab or atezolizumab).
4. Known pregnancy.
5. Patients who progress per the enrolling investigator while on treatment with immune checkpoint inhibitor treatment prior to enrollment.
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants

* to asses serious immediate systemic events,
* to assess local and systemic reaction after Measles-Rubella (MR) vaccine in infants and children,
* to evaluate protectivity and antibody response to measles and rubella after 1 dose of MR vaccine

Eligibility Criteria:
Inclusion Criteria:

* Healthy infants (9-12 months) or children (18-47 months)
* Will receive MR routine immunization.
* Parents have been informed properly regarding the study and signed the informed consent form.
* Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria:

* MR vaccine given simultaneously with other vaccination, except Pentabio (DTP/HB/Hib)
Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy

Autoimmune Membranous Nephropathy is now understood to be a condition caused by the immune system although the exact mechanism is not completely known. This study aims to remove the offending part of the immune system using immunoadsorption to not only treat the disease but also use the opportunity to better understand the mechanism of disease. This will allow more targeted treatment in the future with less complications and side effects.

Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults worldwide. The majority of patients will remain stable with either complete remission or partial remission but approximately 20% will progress slowly to end stage renal disease necessitating the need for renal replacement therapy (RRT).

Current standard therapy for primary (or autoimmune) membranous nephropathy is a regime of rotating high dose steroids and immunosuppression was first described in the mid-nineties and has been the mainstay of treatment since but comes with a high side effect burden.

Idiopathic membranous nephropathy is now understood to be an autoimmune disease characterised by the presence of IgG autoantibodies to M-Type Phospholipase A2 Receptor (anti-PLA2R). Immunoadsorption is a method of removing specific circulating immunoglobulins and has been shown to remove over 80% of circulating IgG with a single session immunoadsorption of 2.5 plasma volumes, with albumin and antithrombin III almost unaffected. With multiple sessions this can rise to over 98%.

Immunoadsorption therapy has been in use for a number of years and this study will use Peptide GAM Immunoadsorption therapy developed by Fresenius Healthcare. This uses two systems, the Art Universal and ADAsorb. The Art Universal became commercially available in 2005 and the ADAsorb in 2002.

Eligibility Criteria:
Inclusion Criteria:

* Biopsy confirmed Primary Membranous Nephropathy within the last 3 years
* Active disease despite 6 months of supportive care including ACEi or ARB (Active disease defined as uPCR \> 300mg/mmol or 24 hour urinary protein \>3.5g/1.73m2)
* Disease severity that in the physicians view warrants treatment prior to completion of 6 months supportive care
* Anti-PLA2R titre \> 170 u/ml
* Haemophilus and Pneumococcal vaccinations up to date
* Above the age of 18
* Able to provide informed consent

Exclusion Criteria:

* Evidence of causes of secondary membranous nephropathy
* eGFR \< 20ml/min
* Treatment with steroids or immunosuppression (including but not limited to cyclophosphamide, MMF or azathioprine) and Biologics (including but limited to Rituximab or belimumab) within 6 months of screening
* Therapeutic Plasma Exchange within 28 days of screening
* Previous renal transplantation
* Co-morbidity, which in physicians' view, would preclude patient from treatment with immunoadsorption.
* Pregnant at time of screening
Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence

During transcutaneous mechanical nerve stimulation in spinal cord injured men an increase in pressure was observed in the external urethral sphincter along with an increase in bladder capacity. In a subsequent study it was demonstrated that Transcutaneous Mechanical Nerve Stimulation (TMNS) in women could induce pressure increment of the external urethral sphincter. A pilot study have since shown that after 6 weeks of stimulation 24 out of 33 women suffering from urinary stress incontinence were able to contract their pelvic floor muscles and had become free of symptoms. Another pilot study has shown promising effect on the overactive bladder syndrome.

The present study aims to treat urinary incontinence and includes 2 groups of patients with 30 patients in each group: Women suffering from urinary stress incontinence and women suffering from urge incontinence. A medical vibrator is used and in each group the subjects will be randomized to vibration treatment or no vibration treatment. All patients will receive pelvic floor training and all women suffering from urge incontinence will receive anticholinergic medications.

The stimulation will be performed at the perineum every day for 6 weeks with an amplitude of 2 mm and a frequency of 100 Hz. Results will be evaluated on the basis of questionnaires, micturition diaries and diaper tests.

If the investigators are able to demonstrate a significant reduction in the incontinence symptoms in the subjects the investigators asses that vibration can be a way of reestablishing a normal function of the pelvic floor muscles and bladder function in incontinent patients.


Eligibility Criteria:
Inclusion Criteria:

* Women suffering from stress incontinence OR Women suffering from urge incontinence /overactive bladder syndrome
* Ongoing anticholinergic treatment in the urge incontinence/overactive bladder syndrome group
* Patient capable of understanding protocol and performing treatment

Exclusion Criteria:

* On going pregnancy or breast feeding
* Treatment with anticholinergic medications in the stress incontinence group
* Treatment with diuretic drugs
* Acute illness (including infection, trauma and haematuria)
* Fibromyalgia
* Faecal incontinence
* Known neurological disease
* Bladder pain syndrome
* Genital prolaps \> stage 2 on the Pelvic Organ Prolapse Quantification System POP-Q
* Previous treatment with neuromodulation or Botox
* Previous pelvic floor surgery or radiation
Enhanced Versus Standard Blood Pressure Lowering on Intracranial Aneurysm Rupture or Growth China Antihypertensive Trial for Intracranial Aneurysm (ChATIA-1)

The goal of this randomized controlled trial is to evaluate the benefits and safety of controlled hypotension in Chinese patients with unruptured intracranial aneurysms(UIA).

The main questions it aims to answer are:

* To provide high-level evidence of the benefits and safety of controlled hypotension in patients with UIA.
* To provide evidence-based medical evidence for blood pressure control of patients with UIA in neurosurgery, and promote the progress of accurate individual management of patients. In this study, the main intervention is enhanced blood pressure lowering in patients with UIA.

All Patients will be randomly assigned to either the standard blood pressure lowering (SBPL) group or the enhanced blood pressure lowering (EBPL) group.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-75;
2. Chinese ethnicity;
3. History of hypertension (as diagnosed per standard of care)
4. Under active treatment for hypertension: In the past one month (before enrollment), the blood pressure was controlled at the borderline statue (systolic pressure as 120-140 mmHg, diastolic pressure as 70-80 mmHg) ;
5. Good medication adherence (Morisky Medication Adherence Scale ≥6)
6. Single unruptured intracranial aneurysm (UIA) identified by computational tomography angiography, magnetic resonance angiography or digital subtraction angiography within 1 year, and receiving conservative treatment
7. Maximal size of UIA at largest dimension \< 7mm;
8. UIA is regular (no bleb(s) or secondary aneurysm(s) protruding from the UIA fundus or bi-/multi-lobular UIA fundus). The regular shape and aneurysm size will be evaluated by the central core lab (including a senior neuroradiologist and two neurosurgeons) based on the three-dimensional angiographic imaging;

Exclusion Criteria:

1. Neurological symptom related to UIA, such as sentinel headache, oculomotor paralysis and so on;
2. Additional active intracranial disease including vasculopathy, arteriovenous malformation/fistula, cancer, traumatic brain injury etc;
3. Fusiform, dissecting, blister, traumatic, mycotic/bacterial, myxomatous, and tumor-associated UIAs are excluded;
4. History of polycystic kidney disease, rheumatic disease or autoimmune disease;
5. Family history of intracranial aneurysm (defined when two direct relatives of patients within three generations have intracranial aneurysms or aneurysmal subarachnoid hemorrhage);
Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

The purpose of this study is to assess the efficacy of Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray as an adjunct treatment of COVID-19.

After being informed about the study and potential risk, all patients giving written informed consent will undergo a brief screening period to determine eligibility for the study. Once eligibility is confirmed, patients who meet the eligibility requirements will be randomized placebo control manner. Patient will be assigned to Xlear (2 puffs per nosetrils, every 3-4 hours a day) or placebo. Patient will be followed for 1 week. Inflammatory markers will be obtained on Day 4 and repeat COVID-19 RT PCR on Day 7. Follow up will be done on Day 14 for all patients.

Eligibility Criteria:
Inclusion Criteria:

1. Adults of ages 18 to 90 years of both sexes
2. With positive SARS-CoV-2 carriage confirmed by nasopharyngeal PCR
3. Signed informed consent
4. 1- Mild symptoms: Minimum respiratory symptoms or asymptomatic plus positive test
5. 2- Moderate symptoms: Respiratory symptoms such as cough, mild shortness of breath with mild oxygen desaturation(room air SpO2 \<92% and \>88% or \<88% corrected to \>92% with 2lt of oxygen)

Exclusion Criteria:

1. Patient with very low viral load (threshold cycle \[Ct\] \> 25 per PCR).
2. Known hypersensitivity to one of the constituents, particularly to xylitol or GSE
3. Under 18 years of age
4. Women of childbearing age who are pregnant, breastfeeding mothers, and intend to become pregnant during the study period; unwilling/unable to take a pregnancy test.
5. Unable to provide informed consent or decline to consent or unwillingness to adhere to the Standard of Care protocol.
6. Patients with severe symptoms -Hypoxia (SpO2 \<88% not corrected by 2 liter non-concentrated oxygen) plus severe shortness of breath
7. History of immunodeficiency or are currently receiving immunosuppressive therapy.
8. Have had a planned surgical procedure within the past 12 weeks.
9. Already part of this trial, recruited at a different hospital.
10. Patient unable to perform oro-nasopharyngeal decolonization
11. Patients with acute exacerbation of severe comorbidities like heart disorders Chronic Obstructive Pulmonary Disease (COPD), Heart Failure New York Heart Association (NYHA) Class 3 and 4 and/or diseases with severe oxygenation problems
12. Patients on Remdesivir and/or other clinical trials.
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

This is a prospective, Phase IV, multi-center, single arm, open-label, interventional study to evaluate the safety of trastuzumab for the treatment of human epidermal growth factor receptor 2 protein (HER2)-positive node positive or high risk node negative breast cancer participants with regimen consisting of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel (AC-TH Regimen) or a regimen consisting of docetaxel and carboplatin (TCH Regimen) in Indian population.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed early invasive HER2 positive, node positive or high risk node negative breast cancer with no evidence of residual, locally recurrent or metastatic disease and defined as clinical stage I to IIIA that is eligible for adjuvant treatment with trastuzumab
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
* HER2 over expression/amplification defined as either Immunohistochemistry (IHC)3+, or IHC2+ and Fluorescence in situ Hybridization (FISH) positive as determined in a central laboratory
* At time of starting trastuzumab therapy, LVEF measured by echocardiography
* Screening LVEF greater than or equal to (\>/=) 55 percent (%)
* Adequate bone marrow, renal, and hepatic function
* Agreement to use an adequate, non-hormonal means of contraception by women of childbearing potential

Exclusion Criteria:

* Any contraindication to trastuzumab
* Previous adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent
* History of other malignancy, except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for at least 5 years
* Past history of ductal carcinoma in situ and/or lobular carcinoma that has been treated with any systemic therapy or with radiation therapy to the ipsilateral breast where the invasive cancer subsequently develops
* Locally advanced (Stage IIIB and IIIC) and metastatic disease (Stage IV)
* Clinically relevant cardiovascular disorder or disease
* Uncontrolled hypertension, or history of hypertensive crisis or hypertensive encephalopathy
* History of severe allergic or immunological reactions, example difficult to control asthma
* Pregnant or lactating women
Adjunct Episcleral Brachytherapy for PCV

This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate response to anti-VEGF monotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Active PCV due to nAMD
* Incomplete response to anti-VEGF
* Received at least 3 consecutive and sequential anti-VEGF injections (no missed treatments)
* Ability to undergo ESB intervention

Exclusion Criteria:

* Sub-retinal fibrosis
* Type I or Type II diabetes mellitus
* Previous therapeutic radiation to the head or neck that may have resulted in radiation dose to the retina
* Study eye with BCVA of worse than 20 ETDRS letters (20/400 Snellen)
* Fellow eye with worse BCVA than the study eye or other vision-threatening disease not eligible for treatment
* Receiving anti-VEGF therapy for any reason other than AMD
The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

How effectively intravenous nalbuphine can reduce the incidence of PONV after intrathecal administration of morphine in abdominoplastic surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing abdominoplasty under spinal anesthesia
* American Society of Anesthesiologists (ASA) class I and II.

Exclusion Criteria:

* allergy to local anesthetics
* bleeding diatheses
* local infection or sepsis
Lymphedema After Urologic Surgery

Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic surgery with lymph node dissection. This project aims to describe the frequency and grade of lymphedema arising after urologic surgery, using the Lymphedema Quality of Life Questionnaire (LymQOL), Delfin MoistureMeter D, and lower limb volume measurements.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing urologic surgery with lymph node dissection

Exclusion Criteria:

* None